Charlottesville, VA, and Pittsburgh, PA, January 10, 2003
Download this FTI news release (PDF).

Biotage, Inc. and Fluorous Technologies, Inc. (FTI) announced today an agreement granting Biotage the exclusive right to manufacture, market, and sell FLASH+® chromatography cartridges and Samplet® sample-loading cartridges containing FTI's FluoroFlash® fluorinated silica. FluoroFlash® fluorinated silica is used for the purification of fluorous tagged molecules.

Fluorous techniques provide strategic options for conducting parallel solution-phase organic synthesis and for separating the resulting reaction mixtures. Fluorous compounds can be readily separated from organics or from each other based on fluorine content by chromatography using FluoroFlash® fluorinated silica. These separations capitalize on the unique feature of fluorous stationary phases to separate molecules primarily by fluorine content. The combination of the two technologies enables synthetic chemists to leverage the FTI synthesis and separation technology with the advantages of Biotage FLASH+® cartridges installed on its automated High-Performance FLASH Chromatography (HPFC) systems.

"We are truly excited by the opportunity for Biotage and FTI to work together," said David Patteson, President and CEO of Biotage. "The combination of FTI's reagents and Biotage's purification platform, in use by nearly 8,000 chemists worldwide, will accelerate the discovery of new compounds by pharmaceutical companies. We view this as a breakthrough technique for synthesis and purification."

"Combining the power of fluourous chemistry with the speed and automation of Biotage's HPFC platform provides a scalable integrated solution to our customers", said Dr. Philip E. Yeske, Chief Operating Officer of FTI. "The combination is a natural fit and one that provides chemists a revolutionary new way to rapidly and efficiently perform synthesis and purification of new compounds."

Contact Information
Biotage
Laurie Creasy Tomko, Marketing Communications Specialist
(434) 220-2617

Fluorous Technologies
Kyle Derstine, Director of Marketing
(412) 826-3059

Biotage, Inc., a wholly-owned subsidiary of Dyax Corp. (Nasdaq: DYAX) of Cambridge, MA, is a global industry leader in small-molecule drug discovery purification systems and consumables for the pharmaceutical industry. Its worldwide headquarters are located in Charlottesville, Virginia, USA with offices in Hertford, England; Duesseldorf, Germany; Milan, Italy and Tokyo, Japan. For additional information, visit www.biotage.com.

Fluorous Technologies, Inc. (FTI) is a chemical technology company dedicated to the development and commercialization of fluorous products focused at the life science market. The company uses patented technology to solve synthesis and separation problems spanning the entire drug discovery and development process. For further information please contact info@fluorous.com or visit www.fluorous.com.

Biotage Disclaimer
This press release contains forward-looking statements, including statements regarding the prospects for the combination of Biotage's HPFC platform products with FluoroFlash® fluorinated silica. Statements that are not historical facts are based on Biotage's current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Biotage competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect the prospects for the combination of Biotage's HPFC platform products with FluoroFlash® fluorinated silica include the risks that: the product combination may not gain market acceptance or may be made less effective or obsolete by competing technologies or products; Biotage may not be able to obtain and maintain intellectual property protection for its products; others may develop technologies or products superior to Biotage's products; and other risk factors described or referred to in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Biotage and Dyax caution investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Biotage and Dyax undertake no obligations to update or revise these statements, except as may be required by law.